The Democratic Republic of Ethiopia, on 14 July 2015, launched an ambitious 10-year national strategy and plan of action to develop local pharmaceutical manufacturing capacity in order to increase access to locally manufactured, quality-assured medicines. The launch occurred on the side-lines of the 3rd Conference on Financing for Development.
Addis Ababa, Brazzaville, 13 July 2015 – The Prime Minister of Ethiopia with the World Health Organization (WHO) launched an ambitious 10-year strategic plan on 14 July to develop its pharmaceutical manufacturing capacity in order to increase access to local quality-assured medicines. The launch took place at an event in the Ethiopian capital, Addis Ababa, on the occasion of the international conference on financing for development and was attended by numerous heads of international agencies.
WHO Emergency use assessment and listing procedures for medical products during public health emergencies.
There are no proven preventive or therapeutic products for Ebola virus disease (EVD).
When WHO and international partners began to fast-track R&D for potential Ebola diagnostics, treatments and vaccines, there was no guidance available on how to test any candidate products in an emergency situation, or how to regulate them.
Ebola specific prevention and treatment tools do not exist at the moment. In response to the severity and breadth of the current epidemic in West Africa, WHO has been spearheading efforts to galvanize the research and development of vaccines, treatments and diagnostics to curb the outbreak and ensure that these tools, if safe and effective, are also available for potential future outbreaks. To that end, WHO has convened the affected countries, donor and scientific communities, civil society and industry to gather the best evidence available and garner support for accelerated development and testing of the most promising tools.
9 July 2015
Recently the World Health Organization (WHO) has received several inquiries on the status of the Ebola vaccine trial in Guinea. An international board of experts known as the Data Safety Monitoring Board met on 3 July 2015 to consider preliminary results for the vaccine efficacy trial. concluded that the trial must continue, so more conclusive evidence can be gathered on the vaccine. ...
02 June 2015
Adverse reactions caused by Falsified Diazepam in Central Africa
11 May 2015
Based on its reviews over the past several years, including the risk of intussusception, GACVS continues to affirm that the safety profile of current rotavirus vaccines is acceptable ...